Tango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 27,000 Shares

Posted by Geri Gentry on May 5th, 2026

Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $21.23, for a total value of $573,210.00. Following the sale, the insider owned 115,743 shares of the company’s stock, valued at $2,457,223.89. The trade was a 18.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Adam Crystal also recently made the following trade(s):

On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The stock was sold at an average price of $25.00, for a total transaction of $961,500.00.
On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.20, for a total transaction of $572,400.00.
On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total transaction of $241,320.00.
On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $303,765.00.
On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $693,985.65.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX traded up $1.49 during midday trading on Tuesday, hitting $24.20. 2,224,178 shares of the stock were exchanged, compared to its average volume of 3,286,227. Tango Therapeutics, Inc. has a 52-week low of $1.03 and a 52-week high of $28.41. The business’s fifty day simple moving average is $19.74 and its two-hundred day simple moving average is $13.44. The company has a market capitalization of $3.49 billion, a PE ratio of -27.82 and a beta of 1.22.

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. As a group, equities analysts anticipate that Tango Therapeutics, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on TNGX. Jefferies Financial Group reiterated a “buy” rating and set a $18.00 price objective on shares of Tango Therapeutics in a report on Thursday, March 5th. Stifel Nicolaus increased their price objective on Tango Therapeutics from $24.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Wall Street Zen lowered Tango Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. HC Wainwright raised their target price on Tango Therapeutics from $13.00 to $27.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, Guggenheim raised their target price on Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, March 6th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.44.

View Our Latest Stock Report on Tango Therapeutics

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new stake in Tango Therapeutics during the fourth quarter valued at approximately $35,000. Dynamic Technology Lab Private Ltd boosted its holdings in Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares in the last quarter. Legal & General Group Plc boosted its holdings in Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after purchasing an additional 1,640 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Tango Therapeutics by 148,800.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after purchasing an additional 4,464 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Tango Therapeutics during the fourth quarter valued at approximately $40,000. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Company Profile

(Get Free Report)

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.